Angelini Pharma has entered into a multi-year collaboration and licensing agreement with Quiver Bioscience to advance new treatments for genetic epilepsies, particularly Developmental and Epileptic Encephalopathies (DEEs).

The partnership combines Quiver’s AI-powered drug discovery platform, proprietary data assets and human neuronal disease models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

Under the agreement, Quiver will receive an undisclosed upfront payment and research funding support, along with licensing fees that provide Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible for milestone payments of up to USD 120 million, in addition to royalties, upon Angelini’s selection of drug targets emerging from the partnership.

Developmental and Epileptic Encephalopathies are rare pediatric disorders caused largely by genetic mutations, leading to severe neurodevelopmental impairments and treatment-resistant seizures. While recent therapies have improved outcomes for certain subtypes, significant unmet medical need remains, particularly in understanding the molecular and functional consequences of gene mutations.

Quiver’s platform integrates single-cell transcriptomics, optical electrophysiology and artificial intelligence-driven analytics to identify precision therapeutic targets. The collaboration aims to generate an unprecedented dataset linking altered neuronal electrophysiology to underlying molecular drivers, potentially accelerating the development of differentiated therapies for multiple DEEs.

Rafal Kaminski, Chief Scientific Officer at Angelini Pharma, said the partnership is expected to generate novel scientific insights through advanced data analytics and AI technologies, creating a foundation for future therapeutic innovation.

Graham T. Dempsey, Co-founder and CEO of Quiver Bioscience, noted that the collaboration leverages functional phenotyping approaches to translate complex genetic insights into potential new medicines for neurological disorders with limited treatment options.

Sergio Marullo di Condojanni, CEO of Angelini Pharma, described the agreement as a strategic step aligned with the company’s efforts to strengthen its global presence and expand its brain health portfolio. The deal follows a series of recent acquisitions and partnerships aimed at reinforcing Angelini Pharma’s leadership in neuroscience.

Destum Partners acted as transaction advisor to Quiver Bioscience.